UBS resumes Charles River Labs stock coverage with buy rating

UBS has resumed coverage of Charles River Laboratories International Inc. (NYSE:CRL) with a buy rating and a price target of $357.00. The firm believes the market is underestimating the positive impact of internalizing non-human primate supply on earnings and that medium-term growth estimates are too low given the strong recovery in biotech markets. Other analysts like JPMorgan, Jefferies, and TD Cowen have also shown positive outlooks for the company.